1. Home
  2. SUI vs UTHR Comparison

SUI vs UTHR Comparison

Compare SUI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUI

Sun Communities Inc.

HOLD

Current Price

$134.58

Market Cap

16.9B

Sector

Real Estate

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$535.53

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUI
UTHR
Founded
1975
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9B
23.9B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
SUI
UTHR
Price
$134.58
$535.53
Analyst Decision
Buy
Buy
Analyst Count
14
14
Target Price
$141.07
$531.79
AVG Volume (30 Days)
786.9K
466.2K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
3.32%
N/A
EPS Growth
1426.76
13.07
EPS
10.84
27.86
Revenue
$2,306,100,000.00
$1,483,300,000.00
Revenue This Year
$6.11
$7.77
Revenue Next Year
$4.80
$11.11
P/E Ratio
$12.45
$19.12
Revenue Growth
N/A
2.38
52 Week Low
$109.22
$266.98
52 Week High
$137.85
$548.12

Technical Indicators

Market Signals
Indicator
SUI
UTHR
Relative Strength Index (RSI) 56.12 62.29
Support Level $124.98 $464.92
Resistance Level $137.85 N/A
Average True Range (ATR) 2.69 19.31
MACD -0.26 4.83
Stochastic Oscillator 59.42 88.41

Price Performance

Historical Comparison
SUI
UTHR

About SUI Sun Communities Inc.

Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: